American Journal of Cardiology
Volume 95, Issue 9 , Pages 1085-1088 , 1 May 2005

Effectiveness of Inhibition of Cholesteryl Ester Transfer Protein by JTT-705 in Combination With Pravastatin in Type II Dyslipidemia

  • Jan Albert Kuivenhoven, PhD

      Affiliations

    • Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    • ,
  • Greetje J. de Grooth, MD, PhD

      Affiliations

    • Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    • ,
  • Hitoshi Kawamura, PhD

      Affiliations

    • AKROS Pharma Inc., Princeton, New Jersey
    • ,
  • Anke H. Klerkx, PhD

      Affiliations

    • Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    • ,
  • Francois Wilhelm, MD, PhD

      Affiliations

    • AKROS Pharma Inc., Princeton, New Jersey
    • ,
  • Mieke D. Trip, MD, PhD

      Affiliations

    • Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    • ,
  • John J.P. Kastelein, MD, PhD

      Affiliations

    • Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    • Corresponding Author InformationDr. Kastelein's address is: Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, Room F4-159.2, 1105 AZ Amsterdam, The Netherlands

Received 22 July 2004 ,Accepted 16 December 2004.

References 

  1. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J, Zwinderman AH, Posma JL, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study . Circulation . 2002;105:2159–2165
  2. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol . N Engl J Med . 2004;350:1505–1515
  3. Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED, Magnus-Aryitey G, et al  Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib . Arterioscler Thromb Vasc Biol . 2004;24:1–9
  4. Barter PJ , Brewer HB , Chapman MJ , Hennekens CH , Rader DJ , Tall AR . Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis . Arterioscler Thromb Vasc Biol . 2003;23:160–167
  5. Warnick GR , Albers JJ . A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol . J Lipid Res . 1978;19:65–76
  6. Friedewald WT , Levy RI , Fredrickson DS . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge . Clin Chem . 1972;18:499–502
  7. Kato H , Nakanishi T , Arai H , Nishida HI , Nishida T . Purification, microheterogeneity, and stability of human lipid transfer protein . J Biol Chem . 1989;264:4082–4087
  8. Sawada S , Sugano M , Makino N , Okamoto H , Tsuchida K . Secretion of pre beta HDL increases with the suppression of cholesteryl ester transfer protein in HepG2 cells . Atherosclerosis . 1999;146:291–298
  9. Illingworth DR. Achievement of low-density lipoprotein cholesterol goals: new strategies to address new guidelines. Cardiol Clin 2003;21:363–375.
  10. Sugano M, Makino N, Sawada S, Otsuka S, Watanabe M, Okamoto H, et al. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits . J Biol Chem . 1998;273:5033–5036

 This study was supported by a grant from AKROS Pharma Inc., Princeton, New Jersey. Dr. Klerkx was supported by a grant from the Dutch Heart Foundation, Amsterdam, The Netherlands (NHS 2000.073 and NHS 2003B191).

PII: S0002-9149(05)00189-X

doi: 10.1016/j.amjcard.2004.12.064

American Journal of Cardiology
Volume 95, Issue 9 , Pages 1085-1088 , 1 May 2005

Article Tools